Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.66 |
| ▸ | CNR1 | P21554 | 2/20 | 0.66 |
| ▸ | KMO | O15229 | 2/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.49 |
| ▸ | XDH | P47989 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17142071 | 0.86 | PTGER1 (0.51) | CNR2CNR1KMOPTGER1XDH | |
| SCHEMBL412103 | 0.81 | KMO (0.55) | CNR2CNR1KMOPTGER1XDH | |
| SCHEMBL2116976 | 0.81 | CNR1 (0.66) | CNR2CNR1KMOPTGER1 | |
| SCHEMBL15774818 | 0.81 | CNR2 (0.60) | CNR2CNR1KMOPTGER1XDH | |
| SCHEMBL17142128 | 0.80 | CNR1 (0.47) | CNR2CNR1KMO | |
| SCHEMBL10271088 | 0.79 | CNR1 (0.53) | CNR2CNR1KMOPTGER1XDH | |
| SCHEMBL410512 | 0.79 | MRGPRX4 (0.49) | CNR2CNR1KMOPTGER1XDH | |
| SCHEMBL28134616 | 0.78 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL3811888 | 0.77 | CNR1 (0.67) | CNR2CNR1PTGER1XDH | |
| SCHEMBL17142039 | 0.77 | KMO (0.49) | CNR2KMOXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | claimed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| CN-111170938-A | 5, 6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | 豪夫迈·罗氏有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3126349-B1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20180327360-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3126349-A1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-20160376237-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2015150438-A1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885CNR1 269/4885KMO 2423/4885 |
| US-20160376237-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CNR2 19/4885CNR1 12/4885KMO 1367/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885CNR1 269/4885KMO 2423/4885 |
| US-20180327360-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CNR2 19/4885CNR1 12/4885KMO 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.